Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Kyverna Therapeutics appointed Greg Martini as Chief Financial Officer, effective May 18, 2026, succeeding Dr. Marc Grasso. Martini joins from Ironwood Pharmaceuticals, where he served as SVP and CFO, bringing deep expertise in capital allocation and commercial-stage growth. The appointment coincides with Kyverna’s advance of its lead asset miv-cel toward potential first approval in stiff person syndrome and its transition to a commercial-stage organization.
Key figures
- Inducement grant shares
- 325000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.